RecruitingPhase 1Phase 2NCT06137118

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

A Phase 1/2 Study to Evaluate the Safety and Efficacy of AZD0486 in Adolescent and Adult Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia

Sponsor

AstraZeneca

Enrollment

255 participants

Start Date

Dec 29, 2023

Study Type

INTERVENTIONAL

Conditions

B-cell Acute Lymphoblastic Leukemia (B-ALL)

Summary

This is a Phase 1/2, global multicentre, open-label, single-arm, dose escalation and dose optimization study of surovatamig (AZD0486) to evaluate the safety, tolerability, and efficacy of surovatamig (AZD0486) monotherapy in participants with R/R B ALL. The study will consist of 4 parts. Part A: monotherapy dose escalation in 3L+ B-ALL. Part B: dose optimization in 3L+ B-ALL. Part C: Dose expansion in 3L+ B-ALL. Part D: Dose optimization and efficacy expansion in R/R B-ALL (2L+)

Eligibility

Min Age: 12 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new drug called AZD0486 for people with B-cell acute lymphoblastic leukemia (B-ALL), a type of blood cancer where the body makes too many immature white blood cells. The drug is a bispecific antibody that targets a protein called CD19 found on cancer cells. **You may be eligible if...** - You are 12 years old or older - You have B-cell ALL with CD19 expression confirmed by a lab test - Your leukemia has come back or stopped responding after at least 2 prior treatments (or 1 treatment if no standard options remain) - Your leukemia cells are present in the bone marrow at 5% or more - Philadelphia chromosome-positive patients may be eligible if they cannot tolerate or have stopped responding to TKI therapy **You may NOT be eligible if...** - Your overall health status is too poor (performance score above 2 for older teens/adults) - You do not meet organ function requirements - You have not had prior treatment failures as described above Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSurovatamig

Investigational Product administered via intravenous infusion.

Locations(82)

Research Site

Birmingham, Alabama, United States

Research Site

Duarte, California, United States

Research Site

Los Angeles, California, United States

Research Site

Palo Alto, California, United States

Research Site

Tampa, Florida, United States

Research Site

Atlanta, Georgia, United States

Research Site

Chicago, Illinois, United States

Research Site

New York, New York, United States

Research Site

Houston, Texas, United States

Research Site

Richmond, Virginia, United States

Research Site

Seattle, Washington, United States

Research Site

Milwaukee, Wisconsin, United States

Research Site

Melbourne, Australia

Research Site

Porto Alegre, Brazil

Research Site

São Paulo, Brazil

Research Site

São Paulo, Brazil

Research Site

Toronto, Ontario, Canada

Research Site

Montreal, Quebec, Canada

Research Site

Montreal, Quebec, Canada

Research Site

Changsha, China

Research Site

Chengdu, China

Research Site

Guangzhou, China

Research Site

Guangzhou, China

Research Site

Hangzhou, China

Research Site

Nanjing, China

Research Site

Nanjing, China

Research Site

Suzhou, China

Research Site

Tianjin, China

Research Site

Zhengzhou, China

Research Site

Caen, France

Research Site

Marseille, France

Research Site

Nantes, France

Research Site

Paris, France

Research Site

Pierre-Bénite, France

Research Site

Toulouse, France

Research Site

Berlin, Germany

Research Site

Cologne, Germany

Research Site

Düsseldorf, Germany

Research Site

Essen, Germany

Research Site

Frankfurt, Germany

Research Site

Freiburg im Breisgau, Germany

Research Site

Halle, Germany

Research Site

Hamburg, Germany

Research Site

Kiel, Germany

Research Site

München, Germany

Research Site

Münster, Germany

Research Site

Würzburg, Germany

Research Site

Bergamo, Italy

Research Site

Bologna, Italy

Research Site

Monza, Italy

Research Site

Naples, Italy

Research Site

Roma, Italy

Research Site

Bunkyō City, Japan

Research Site

Chiba, Japan

Research Site

Chūōku, Japan

Research Site

Fukuoka, Japan

Research Site

Kashiwa, Japan

Research Site

Kyoto, Japan

Research Site

Okayama, Japan

Research Site

Osaka, Japan

Research Site

Sapporo, Japan

Research Site

Toyohashi, Japan

Research Site

Yamagata, Japan

Research Site

Seoul, South Korea

Research Site

Seoul, South Korea

Research Site

Seoul, South Korea

Research Site

Seoul, South Korea

Research Site

Seoul, South Korea

Research Site

Barcelona, Spain

Research Site

Barcelona, Spain

Research Site

Madrid, Spain

Research Site

Madrid, Spain

Research Site

Salamanca, Spain

Research Site

Valencia, Spain

Research Site

Kaohsiung City, Taiwan

Research Site

Taichung, Taiwan

Research Site

Tainan, Taiwan

Research Site

Taipei, Taiwan

Research Site

Taoyuan, Taiwan

Research Site

London, United Kingdom

Research Site

Manchester, United Kingdom

Research Site

Surrey, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06137118

Related Trials

Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol

NCT0676423827 locations

A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia

NCT072053152 locations

Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

NCT0710921926 locations

Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)

NCT054804491 location

CAR T-cell Long-Term Follow-Up, Quality of Life and Adverse Reactions

NCT070485351 location